These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8541563)

  • 21. Serum BCL2/IGH DNA in follicular lymphoma patients: a minimal residual disease marker.
    Gocke CD; Kopreski MS; Benko FA; Sternas L; Kwak LW
    Leuk Lymphoma; 2000 Sep; 39(1-2):165-72. PubMed ID: 10975396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunophenotypic and cytogenetic findings of B-lymphoblastic leukemia/lymphoma associated with combined IGH/BCL2 and MYC rearrangement.
    Kelemen K; Holden J; Johnson LJ; Davion S; Robetorye RS
    Cytometry B Clin Cytom; 2017 Jul; 92(4):310-314. PubMed ID: 26517296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources.
    Léonard BM; Hétu F; Busque L; Gyger M; Bélanger R; Perreault C; Roy DC
    Blood; 1998 Jan; 91(1):331-9. PubMed ID: 9414302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation.
    Zwicky CS; Maddocks AB; Andersen N; Gribben JG
    Blood; 1996 Nov; 88(9):3314-22. PubMed ID: 8896395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Follicular lymphoma with a novel t(14;18) breakpoint involving the immunoglobulin heavy chain switch mu region indicates an origin from germinal center B cells.
    Fenton JA; Vaandrager JW; Aarts WM; Bende RJ; Heering K; van Dijk M; Morgan G; van Noesel CJ; Schuuring E; Kluin PM
    Blood; 2002 Jan; 99(2):716-8. PubMed ID: 11781262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bcl-2/IgH expression in minimal bone marrow infiltration by follicular lymphoma cells.
    Che YQ; Liu P; Wang Y; Zhang CG; Han YL; Shen D; Zhang Y; Zheng CL; Qi J; Wang QT
    Mol Med Rep; 2012 Feb; 5(2):383-7. PubMed ID: 22052344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
    Pilarski LM; Belch AR
    Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas.
    Soubeyran P; Hostein I; Debled M; Eghbali H; Soubeyran I; Bonichon F; Astier-Gin T; Hoerni B
    Br J Cancer; 1999 Nov; 81(5):860-9. PubMed ID: 10555759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease.
    Andersen NS; Donovan JW; Borus JS; Poor CM; Neuberg D; Aster JC; Nadler LM; Freedman AS; Gribben JG
    Blood; 1997 Nov; 90(10):4212-21. PubMed ID: 9354694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bcl-2/IgH expression of diffuse large B-cell lymphoma cells in minimal bone marrow infiltration.
    Che YQ; Liu P; Luo Y; Shen D; Hao JJ; Yang L; Zhang CG; Qi J; Wang MR
    Clin Lab; 2014; 60(6):989-98. PubMed ID: 25016705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral follicular lymphomas. A short report of 8 cases with assessment of the IGH/BCL2 gene fusion with fluorescence in situ hybridization.
    Argyris PP; Dolan M; Piperi E; Tosios KI; Pambuccian SE; Koutlas IG
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Sep; 116(3):343-7. PubMed ID: 23953419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations.
    Negrin RS; Pesando J
    J Clin Oncol; 1994 May; 12(5):1021-7. PubMed ID: 8164025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations.
    Ladetto M; Mantoan B; De Marco F; Drandi D; Aguzzi C; Astolfi M; Vallet S; Ricca I; Dell' Aquila M; Pagliano G; Monitillo L; Pollio B; Santo L; Cristiano C; Rocci A; Francese R; Bodoni CL; Borchiellini A; Schinco P; Boccadoro M; Tarella C
    Exp Hematol; 2006 Dec; 34(12):1680-6. PubMed ID: 17157165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD34 selections from myeloma peripheral blood cell autografts contain residual tumour cells due to impurity, not to CD34+ myeloma cells.
    Willems P; Croockewit A; Raymakers R; Holdrinet R; van Der Bosch G; Huys E; Mensink E
    Br J Haematol; 1996 Jun; 93(3):613-22. PubMed ID: 8652382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative preclinical study of three bone marrow purging methods using PCR evaluation of residual t(14;18) lymphoma cells.
    Yerly-Motta V; Racadot E; Fest T; Bastard C; Ferrand C; Deschaseaux ML; Herve P
    Leuk Lymphoma; 1996 Oct; 23(3-4):313-21. PubMed ID: 9031112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow.
    Gribben JG; Neuberg D; Barber M; Moore J; Pesek KW; Freedman AS; Nadler LM
    Blood; 1994 Jun; 83(12):3800-7. PubMed ID: 8204898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
    Della Starza I; Cavalli M; De Novi LA; Genuardi E; Mantoan B; Drandi D; Barbero D; Ciabatti E; Grassi S; Gazzola A; Mannu C; Agostinelli C; Piccaluga PP; Bomben R; Degan M; Gattei V; Guarini A; Foà R; Galimberti S; Ladetto M; Ferrero S; Del Giudice I;
    Hematol Oncol; 2019 Oct; 37(4):368-374. PubMed ID: 31325190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma.
    Hamamoto Y; Kukita Y; Kitamura M; Kurashige M; Masaie H; Fuji S; Ishikawa J; Honma K; Wakasa T; Hanamoto H; Hirokawa M; Suzuki A; Morii E; Nakatsuka SI
    Histopathology; 2021 Oct; 79(4):521-532. PubMed ID: 33829512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma.
    Barreca A; Martinengo C; Annaratone L; Righi L; Chiappella A; Ladetto M; Demurtas A; Chiusa L; Stacchini A; Crosetto N; van Oudenaarden A; Chiarle R
    Blood Cancer J; 2014 Oct; 4(10):e249. PubMed ID: 25303368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of bone marrow involvement by clonal immunoglobulin gene rearrangements in follicular lymphoma.
    Berget E; Helgeland L; Liseth K; Løkeland T; Molven A; Vintermyr OK
    J Clin Pathol; 2014 Dec; 67(12):1072-7. PubMed ID: 25233852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.